Cargando…

Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment

Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottensmeier, Holger, Schlegel, Paul G., Eyrich, Matthias, Wolff, Johannes E., Juhnke, Björn-Ole, von Hoff, Katja, Frahsek, Stefanie, Schmidt, Rene, Faldum, Andreas, Fleischhack, Gudrun, von Bueren, Andre, Friedrich, Carsten, Resch, Anika, Warmuth-Metz, Monika, Krauss, Jürgen, Kortmann, Rolf D., Bode, Udo, Kühl, Joachim, Rutkowski, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977734/
https://www.ncbi.nlm.nih.gov/pubmed/31971950
http://dx.doi.org/10.1371/journal.pone.0227693
_version_ 1783490576048455680
author Ottensmeier, Holger
Schlegel, Paul G.
Eyrich, Matthias
Wolff, Johannes E.
Juhnke, Björn-Ole
von Hoff, Katja
Frahsek, Stefanie
Schmidt, Rene
Faldum, Andreas
Fleischhack, Gudrun
von Bueren, Andre
Friedrich, Carsten
Resch, Anika
Warmuth-Metz, Monika
Krauss, Jürgen
Kortmann, Rolf D.
Bode, Udo
Kühl, Joachim
Rutkowski, Stefan
author_facet Ottensmeier, Holger
Schlegel, Paul G.
Eyrich, Matthias
Wolff, Johannes E.
Juhnke, Björn-Ole
von Hoff, Katja
Frahsek, Stefanie
Schmidt, Rene
Faldum, Andreas
Fleischhack, Gudrun
von Bueren, Andre
Friedrich, Carsten
Resch, Anika
Warmuth-Metz, Monika
Krauss, Jürgen
Kortmann, Rolf D.
Bode, Udo
Kühl, Joachim
Rutkowski, Stefan
author_sort Ottensmeier, Holger
collection PubMed
description Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German brain tumour trials HIT2000 and HIT-REZ2005. Testing was performed using the validated Wuerzburg Intelligence Diagnostics (WUEP-D), which includes Kaufman-Assessment-Battery, Coloured Progressive Matrices, Visual-Motor Integration, finger tapping “Speed”, and the Continuous Performance Test. Of 104 patients in 47 centres, 72 were eligible for analyses. We assessed whether IQ was impacted by disease extent, disease location, patient age, gender, age at surgery, and treatment (chemotherapy with our without craniospinal irradiation [CSI] or local radiotherapy [LRT]). Median age at surgery was 2.3 years. Testing was performed at a median of 4.9 years after surgery. Patients with infratentorial EPs (treated with LRT) scored highest in fluid intelligence (CPM 100.9±16.9, mean±SD); second best scores were achieved by patients with MB without metastasis treated with chemotherapy alone (CPM 93.9±13.2), followed by patients with supratentorial EPs treated with LRT. In contrast, lowest scores were achieved by patients that received chemotherapy and CSI, which included children with metastasised MB and those with relapsed MB M0 (CPM 71.7±8.0 and 73.2±21.8, respectively). Fine motor skills were reduced in all groups. Multivariable analysis revealed that type of treatment had an impact on IQ, but essentially not age at surgery, time since surgery or gender. Our results confirm previous reports on the detrimental effects of CSI in a larger cohort of children. Comparable IQ scores in children with MB treated only with chemotherapy and in children with EP suggest that this treatment strategy represents an attractive option for children who have a high chance to avoid application of CSI. Longitudinal follow-up examinations are warranted to assess long-term neuropsychological outcomes.
format Online
Article
Text
id pubmed-6977734
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-69777342020-02-07 Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment Ottensmeier, Holger Schlegel, Paul G. Eyrich, Matthias Wolff, Johannes E. Juhnke, Björn-Ole von Hoff, Katja Frahsek, Stefanie Schmidt, Rene Faldum, Andreas Fleischhack, Gudrun von Bueren, Andre Friedrich, Carsten Resch, Anika Warmuth-Metz, Monika Krauss, Jürgen Kortmann, Rolf D. Bode, Udo Kühl, Joachim Rutkowski, Stefan PLoS One Research Article Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German brain tumour trials HIT2000 and HIT-REZ2005. Testing was performed using the validated Wuerzburg Intelligence Diagnostics (WUEP-D), which includes Kaufman-Assessment-Battery, Coloured Progressive Matrices, Visual-Motor Integration, finger tapping “Speed”, and the Continuous Performance Test. Of 104 patients in 47 centres, 72 were eligible for analyses. We assessed whether IQ was impacted by disease extent, disease location, patient age, gender, age at surgery, and treatment (chemotherapy with our without craniospinal irradiation [CSI] or local radiotherapy [LRT]). Median age at surgery was 2.3 years. Testing was performed at a median of 4.9 years after surgery. Patients with infratentorial EPs (treated with LRT) scored highest in fluid intelligence (CPM 100.9±16.9, mean±SD); second best scores were achieved by patients with MB without metastasis treated with chemotherapy alone (CPM 93.9±13.2), followed by patients with supratentorial EPs treated with LRT. In contrast, lowest scores were achieved by patients that received chemotherapy and CSI, which included children with metastasised MB and those with relapsed MB M0 (CPM 71.7±8.0 and 73.2±21.8, respectively). Fine motor skills were reduced in all groups. Multivariable analysis revealed that type of treatment had an impact on IQ, but essentially not age at surgery, time since surgery or gender. Our results confirm previous reports on the detrimental effects of CSI in a larger cohort of children. Comparable IQ scores in children with MB treated only with chemotherapy and in children with EP suggest that this treatment strategy represents an attractive option for children who have a high chance to avoid application of CSI. Longitudinal follow-up examinations are warranted to assess long-term neuropsychological outcomes. Public Library of Science 2020-01-23 /pmc/articles/PMC6977734/ /pubmed/31971950 http://dx.doi.org/10.1371/journal.pone.0227693 Text en © 2020 Ottensmeier et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ottensmeier, Holger
Schlegel, Paul G.
Eyrich, Matthias
Wolff, Johannes E.
Juhnke, Björn-Ole
von Hoff, Katja
Frahsek, Stefanie
Schmidt, Rene
Faldum, Andreas
Fleischhack, Gudrun
von Bueren, Andre
Friedrich, Carsten
Resch, Anika
Warmuth-Metz, Monika
Krauss, Jürgen
Kortmann, Rolf D.
Bode, Udo
Kühl, Joachim
Rutkowski, Stefan
Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
title Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
title_full Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
title_fullStr Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
title_full_unstemmed Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
title_short Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
title_sort treatment of children under 4 years of age with medulloblastoma and ependymoma in the hit2000/hit-rez 2005 trials: neuropsychological outcome 5 years after treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977734/
https://www.ncbi.nlm.nih.gov/pubmed/31971950
http://dx.doi.org/10.1371/journal.pone.0227693
work_keys_str_mv AT ottensmeierholger treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT schlegelpaulg treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT eyrichmatthias treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT wolffjohannese treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT juhnkebjornole treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT vonhoffkatja treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT frahsekstefanie treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT schmidtrene treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT faldumandreas treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT fleischhackgudrun treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT vonbuerenandre treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT friedrichcarsten treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT reschanika treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT warmuthmetzmonika treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT kraussjurgen treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT kortmannrolfd treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT bodeudo treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT kuhljoachim treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment
AT rutkowskistefan treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment